At close: September 27 at 4:00 PM EDT
After hours: September 27 at 7:52 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 12 |
| Avg. Estimate | -1.72 | -1.65 | -8.93 | -6.46 |
| Low Estimate | -2.19 | -2.19 | -10.23 | -8.55 |
| High Estimate | -1.3 | -0.44 | -6.74 | -5.54 |
| Year Ago EPS | -1.5 | -1.81 | -5.73 | -8.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 12 | 11 |
| Avg. Estimate | -- | 10M | 8.33M | 20M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | 100M | 100M | 63.83M |
| Year Ago Sales | -- | -- | -- | 8.33M |
| Sales Growth (year/est) | -- | -- | -- | 140.10% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.34 | -1.41 | -1.57 | -1.77 |
| EPS Actual | -1.5 | -1.81 | -2.2 | -3.64 |
| Difference | -0.16 | -0.4 | -0.63 | -1.87 |
| Surprise % | -11.90% | -28.40% | -40.10% | -105.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.72 | -1.65 | -8.93 | -6.46 |
| 7 Days Ago | -1.73 | -1.66 | -8.95 | -6.7 |
| 30 Days Ago | -1.73 | -1.68 | -8.99 | -6.72 |
| 60 Days Ago | -1.7 | -1.66 | -7.26 | -6.63 |
| 90 Days Ago | -1.72 | -1.67 | -7.32 | -6.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 2 | 6 |
| Up Last 30 Days | 2 | 3 | 2 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | BHVN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -14.70% | -- | -- | 5.60% |
| Next Qtr. | 8.80% | -- | -- | 9.90% |
| Current Year | -55.80% | -- | -- | 3.40% |
| Next Year | 27.70% | -- | -- | 12.70% |
| Next 5 Years (per annum) | -- | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 8/19/2024 |
| Maintains | UBS: Buy to Buy | 8/13/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 8/12/2024 |
| Initiated | Morgan Stanley: Overweight | 7/24/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 6/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/30/2024 |
Related Tickers
BDTX Black Diamond Therapeutics, Inc.
4.2300
-4.08%
EWTX Edgewise Therapeutics, Inc.
26.09
+0.38%
WVE Wave Life Sciences Ltd.
8.29
+3.37%
CAPR Capricor Therapeutics, Inc.
9.95
-0.40%
CRBP Corbus Pharmaceuticals Holdings, Inc.
20.92
-2.65%
CLDX Celldex Therapeutics, Inc.
33.20
+1.03%
APLS Apellis Pharmaceuticals, Inc.
29.47
-1.27%
SMMT Summit Therapeutics Inc.
20.89
-8.44%
ELYM Eliem Therapeutics, Inc.
4.9800
-0.40%
GPCR Structure Therapeutics Inc.
41.75
+0.53%